The Global Biological Standards Institute has determined that material and procedural standards
are the key battleground for improving the reproducibility of preclinical
studies-an area of growing concern among funding agencies and industry
stakeholders.1-4 This year the institute will form task forces that
will begin developing standards in research areas in which the institute deems
they are most needed, such as human cancer cell lines, antibody reagents and
next-generation genome sequencing.
Calling for consensus
Back to basics
M.J. SciBX 7(3);
Published online Jan. 23, 2014
1. Begley, C.G. &
Ellis, L.M. Nature 483, 531-533 (2012)
2. Bissell, M. Nature
503, 333-334 (2013)
3. Freedman, L. Nature
504, 376 (2013)
4. Haibe-Kains, B. et
al. Nature 504, 389-393 (2013)
5. Fulmer, T. SciBX
6. Global Biological
Standards Institute. The case for standards in life science research:
seizing opportunities at a time of critical need.
7. Capes-Davis, A. et
al. Int. J. Cancer 127, 1-8 (2010)
Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
Clinical and Laboratory Standards Institute, Wayne, Pa.
Food and Drug Administration, Silver Spring, Md.
Global Biological Standards Institute, Washington, D.C.
Jefferson Medical College at Thomas Jefferson University, Philadelphia, Pa.
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J.
for Advancing Translational Sciences, Bethesda, Md.
National Institute of Standards and Technology, Gaithersburg, Md.
National Institutes of Health, Bethesda, Md.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
San Francisco, Calif.
Science Exchange, Palo Alto, Calif.
TetraLogic Pharmaceuticals Corp., Malvern, Pa.
University of Maryland, College Park, Md.